CLINICAL_TRIALS
trial_result
· 2020-09-01
Clinical Trial Update: A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma [Phase 2]
Summary
Phase 2 study of tivozanib (AV-951) in renal cell carcinoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2020-09-01